Publication
Date | SPC No. | SPC
Category | Details
Rows may repeat to show multiple inventors or applicants depending on "Sort By" |
|---|
20 July 2016
(Journal 6635)
| SPC/GB05/033 | Entered Into Force | Applicant: EISAI R&D MANAGEMENT CO., LTD
Koishikawa 4-6-10, Bunkyo-ku, Tokyo 112-8088, Japan
Product: Ziconotide, optionally in the form of a salt with a pharmaceutically acceptable acid, including ziconotide acetate
Product Type: Medicinal
Authorised: UK EU/1/04/302/001 24 February 2005
UK EU/1/04/302/002 24 February 2005
UK EU/1/04/302/003 24 February 2005
Authorised Extension:
Patent No: EP0835126
Title: Compositions and Formulations for Producing Analgesia and for Inhibiting Progression of Neuropathic Pain Disorders
SPC No: SPC/GB05/033
Date entered into force: 26 June 2016
Effective Period Expires On: 23 February 2020 |
20 July 2016
(Journal 6635)
| SPC/GB09/047 | Entered Into Force | Applicant: BIAL - Portela & CA, S.A.
A Av. da Siderugia Nacional, 4745-457 S. Mamede do Coronado, Portugal
Product: Eslicarbazepine acetate
Product Type: Medicinal
Authorised: UK EU/1/09/514/001 21 April 2009
UK EU/1/09/514/002 21 April 2009
UK EU/1/09/514/003 21 April 2009
UK EU/1/09/514/004 21 April 2009
UK EU/1/09/514/005 21 April 2009
UK EU/1/09/514/006 21 April 2009
UK EU/1/09/514/007 21 April 2009
UK EU/1/09/514/008 21 April 2009
UK EU/1/09/514/009 21 April 2009
UK EU/1/09/514/010 21 April 2009
UK EU/1/09/514/011 21 April 2009
UK EU/1/09/514/012 21 April 2009
UK EU/1/09/514/013 21 April 2009
UK EU/1/09/514/014 21 April 2009
UK EU/1/09/514/015 21 April 2009
UK EU/1/09/514/016 21 April 2009
UK EU/1/09/514/017 21 April 2009
UK EU/1/09/514/018 21 April 2009
UK EU/1/09/514/019 21 April 2009
UK EU/1/09/514/020 21 April 2009
Authorised Extension:
Patent No: EP0751129
Title: Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
SPC No: SPC/GB09/047
Date entered into force: 28 June 2016
Effective Period Expires On: 27 June 2021 |
20 July 2016
(Journal 6635)
| SPC/GB13/016 | Expired | Applicant: Bayer Intellectual Property GmbH
Alfred-Nobel-Strasse 10, 40789 Monheim am Rhein, Germany
Product: Flufenacet and Pendimethalin
Product Type: Plant Protection
Authorised: UK 1389/2001 27 June 2001
UK 1390/2001 27 June 2001
UK 1391/2001 27 June 2001
UK 1392/2001 27 June 2001
UK 1393/2001 27 June 2001
UK 1394/2001 27 June 2001
UK 1395/2001 27 June 2001
UK 1396/2001 27 June 2001
Authorised Extension:
Patent No: EP2213170
Title: Herbicidal agents based on Heteroaryloxyacetamides
SPC No: SPC/GB13/016
Date Expired: 26 June 2016 |
20 July 2016
(Journal 6635)
| SPC/GB14/037 | Entered Into Force | Applicant: Zoetis Services LLC
100 Campus Drive, Florham Park, New Jersey 07932, United States of America
Product: Derquantel, optionally in the form of pharmaceutically acceptable salts.
Product Type: Medicinal
Authorised: UK Vm00057/4420 13 January 2012
Authorised Extension:
Patent No: EP1489082
Title: Intermediate Compounds
SPC No: SPC/GB14/037
Date entered into force: 26 June 2016
Effective Period Expires On: 25 June 2021 |
20 July 2016
(Journal 6635)
| | Lodged | Supplementary protection Certificate No SPC/GB13/045 in the name of Novartis AG in respect of the product “The combination of Neisseria meningitidis group B NHBA fusion protein, Neisseria meningitidis group B NadA protein, and Neisseria meningitidis group B fHbp fusion protein.”, the filing of which was advertised in Journal No 6481 dated 07/08/2013 has had the date of the marketing authorisation corrected to 18/01/2013. |
20 July 2016
(Journal 6635)
| | Lodged | Supplementary Protection Certificate No SPC/GB13/044 filed by Novartis AG in respect of the product “Outer membrane vesicles (OMV) from Neisseria meningitidis group B”, the filing of which was advertised in journal No 6481 dated 07/08/2013 has had the date of the marketing authorisation corrected to 18/01/2013. |
20 July 2016
(Journal 6635)
| | Granted | Supplementary Protection Certificate No SPC/GB11/049 granted to Gilead Sciences, Inc. in respect of the product “Aztreonam lysine”, the grant of which was advertised in journal No 6596 dated 21/10/2015 has had its maximum period of duration corrected, subject to the payment of the prescribed fees it will expire on 22/09/2024. |
